A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients | Zendy

Berthold-Josef Rzany | Zendy; Benjamin Ascher | Zendy; Rui L. Avelar | Zendy; Jesper Bergdahl | Zendy; Vince Bertucci | Zendy; Isaac Bodokh | Zendy; James Alastair Carruthers | Zendy; Hugues Cartier | Zendy; Henry Delmar | Zendy; Ralf Denfeld | Zendy; John E. Gross | Zendy; Marc Heckmann | Zendy; Per Hedén | Zendy; Said Hilton | Zendy; Christopher Inglefield | Zendy; Patricia Ogilvie | Zendy; Gerhard Sattler | Zendy; Michael Sebastian | Zendy; Nowell Solish | Zendy; Arthur Swift | Zendy; Patrick Trévidic | Zendy

Open Access

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients

Author(s) -

Berthold-Josef Rzany,

Benjamin Ascher,

Rui L. Avelar,

Jesper Bergdahl,

Vince Bertucci,

Isaac Bodokh,

James Alastair Carruthers,

Hugues Cartier,

Henry Delmar,

Ralf Denfeld,

John E. Gross,

Marc Heckmann,

Per Hedén,

Said Hilton,

Christopher Inglefield,

Patricia Ogilvie,

Gerhard Sattler,

Michael Sebastian,

Nowell Solish,

Arthur Swift,

Patrick Trévidic

Publication year - 2019

Publication title -

aesthetic surgery journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.528

H-Index - 58

eISSN - 1527-330X

pISSN - 1090-820X

DOI - 10.1093/asj/sjz110

Subject(s) - medicine , placebo , clinical endpoint , confidence interval , adverse effect , randomized controlled trial , surgery , pathology , alternative medicine

PrabotulinumtoxinA is a 900-kDa botulinum toxin type A produced by Clostridium botulinum.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research